JP2021523702A - ヒト抗ａａｖ２カプシドポリクローナル抗体エピトープ - Google Patents

ヒト抗ａａｖ２カプシドポリクローナル抗体エピトープ Download PDF

Info

Publication number
JP2021523702A
JP2021523702A JP2020561751A JP2020561751A JP2021523702A JP 2021523702 A JP2021523702 A JP 2021523702A JP 2020561751 A JP2020561751 A JP 2020561751A JP 2020561751 A JP2020561751 A JP 2020561751A JP 2021523702 A JP2021523702 A JP 2021523702A
Authority
JP
Japan
Prior art keywords
aav
capsid
seq
epitope
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020561751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523702A5 (https=
JPWO2019213668A5 (https=
Inventor
圭 足立
圭 足立
チャン，シャオ，ラン
浩之 中井
浩之 中井
Original Assignee
オレゴン ヘルス アンド サイエンス ユニバーシティ
オレゴン ヘルス アンド サイエンス ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オレゴン ヘルス アンド サイエンス ユニバーシティ, オレゴン ヘルス アンド サイエンス ユニバーシティ filed Critical オレゴン ヘルス アンド サイエンス ユニバーシティ
Publication of JP2021523702A publication Critical patent/JP2021523702A/ja
Publication of JP2021523702A5 publication Critical patent/JP2021523702A5/ja
Publication of JPWO2019213668A5 publication Critical patent/JPWO2019213668A5/ja
Priority to JP2024079802A priority Critical patent/JP2024119818A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020561751A 2018-05-04 2019-05-06 ヒト抗ａａｖ２カプシドポリクローナル抗体エピトープ Pending JP2021523702A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024079802A JP2024119818A (ja) 2018-05-04 2024-05-15 ヒト抗ａａｖ２カプシドポリクローナル抗体エピトープ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862667360P 2018-05-04 2018-05-04
US62/667,360 2018-05-04
PCT/US2019/030955 WO2019213668A1 (en) 2018-05-04 2019-05-06 Human anti-aav2 capsid polyclonal antibody epitopes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024079802A Division JP2024119818A (ja) 2018-05-04 2024-05-15 ヒト抗ａａｖ２カプシドポリクローナル抗体エピトープ

Publications (3)

Publication Number Publication Date
JP2021523702A true JP2021523702A (ja) 2021-09-09
JP2021523702A5 JP2021523702A5 (https=) 2022-05-16
JPWO2019213668A5 JPWO2019213668A5 (https=) 2022-05-16

Family

ID=68386753

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561751A Pending JP2021523702A (ja) 2018-05-04 2019-05-06 ヒト抗ａａｖ２カプシドポリクローナル抗体エピトープ
JP2024079802A Pending JP2024119818A (ja) 2018-05-04 2024-05-15 ヒト抗ａａｖ２カプシドポリクローナル抗体エピトープ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024079802A Pending JP2024119818A (ja) 2018-05-04 2024-05-15 ヒト抗ａａｖ２カプシドポリクローナル抗体エピトープ

Country Status (5)

Country Link
US (1) US20210292370A1 (https=)
EP (1) EP3799568A4 (https=)
JP (2) JP2021523702A (https=)
CN (1) CN112351787A (https=)
WO (1) WO2019213668A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025100417A1 (ja) * 2023-11-06 2025-05-15 株式会社ダイセル Ａａｖのフルカプシドに対するアフィニティポリペプチド

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3861010A1 (en) 2018-10-02 2021-08-11 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
IL293658A (en) * 2019-12-10 2022-08-01 Homology Medicines Inc Adeno-associated virus preparations and a method of using them
US12209251B2 (en) 2020-05-05 2025-01-28 The University Of North Carolina At Chapel Hill Modified adeno-associated virus 5 capsids and uses thereof
CN116096734A (zh) 2020-05-13 2023-05-09 沃雅戈治疗公司 Aav衣壳的向性的重定向
CN113583112B (zh) * 2021-07-30 2022-07-19 上海勉亦生物科技有限公司 Aav特异性抗体及其应用
CN113999861B (zh) * 2021-09-08 2024-03-15 三峡大学 腺相关病毒衣壳蛋白保守区多克隆抗体的制备方法及应用
MX2024004936A (es) 2021-11-02 2024-05-08 Voyager Therapeutics Inc Variantes de capsides de aav y sus usos.
CN114685651B (zh) * 2022-04-15 2023-07-11 三峡大学 一种特异识别aav9衣壳蛋白的多克隆抗体及制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519895A (ja) * 2012-05-15 2015-07-16 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 高形質導入効率ｒＡＡＶベクター、組成物、および使用方法
US20170067908A1 (en) * 2014-04-25 2017-03-09 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
WO2017058892A2 (en) * 2015-09-28 2017-04-06 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
WO2017197355A2 (en) * 2016-05-13 2017-11-16 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7749492B2 (en) * 2001-01-05 2010-07-06 Nationwide Children's Hospital, Inc. AAV vectors and methods
EP1828390B1 (en) * 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
DK2675902T3 (da) * 2011-02-17 2019-06-03 Univ Pennsylvania Sammensætninger og fremgangsmåder til at ændre vævsspecificitet og forbedre aav9-medieret genoverførsel
US20140162319A2 (en) * 2012-05-02 2014-06-12 Sangeetha Hareendran Nucleotide sequences, methods, kit and a recombinant cell thereof
US11136557B2 (en) * 2013-05-31 2021-10-05 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
BR112020007405A2 (pt) * 2017-10-18 2020-12-08 Regenxbio Inc. Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519895A (ja) * 2012-05-15 2015-07-16 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 高形質導入効率ｒＡＡＶベクター、組成物、および使用方法
US20170067908A1 (en) * 2014-04-25 2017-03-09 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
WO2017058892A2 (en) * 2015-09-28 2017-04-06 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
WO2017197355A2 (en) * 2016-05-13 2017-11-16 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF VIROLOGY, vol. 74, no. 18, JPN6023019754, 2000, pages 8635 - 8647, ISSN: 0005238011 *
JOURNAL OF VIROLOGY, vol. 86, no. 15, JPN6023019751, 2012, pages 7739 - 7751, ISSN: 0005238008 *
MOLECULAR THERAPY, vol. 22, no. 11, JPN6023019753, 2014, pages 1900 - 1909, ISSN: 0005238010 *
NATURE BIOTECHNOLOGY, vol. 24, no. 2, JPN6023019750, 2006, pages 198 - 204, ISSN: 0005060793 *
NATURE COMMUNICATIONS, vol. Vol.5:3075, JPN6023019752, 2014, pages 1 - 14, ISSN: 0005238009 *
PLOS ONE, vol. 8, no. 3, JPN6023019755, 2013, pages 59142 - 1, ISSN: 0005238012 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025100417A1 (ja) * 2023-11-06 2025-05-15 株式会社ダイセル Ａａｖのフルカプシドに対するアフィニティポリペプチド

Also Published As

Publication number Publication date
EP3799568A4 (en) 2022-07-06
EP3799568A1 (en) 2021-04-07
CN112351787A (zh) 2021-02-09
US20210292370A1 (en) 2021-09-23
JP2024119818A (ja) 2024-09-03
WO2019213668A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
US11572637B2 (en) Methods of viral neutralizing antibody epitope mapping
JP2021523702A (ja) ヒト抗ａａｖ２カプシドポリクローナル抗体エピトープ
Peabody et al. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2
US9856469B2 (en) AAV capsid proteins for nucleic acid transfer
US9683268B2 (en) Viruses associated with immunodeficiency and enteropathy and methods using same
WO2022184027A1 (zh) 一种新型冠状病毒多价抗原、其制备方法和应用
US5218099A (en) Post-transfusion, non-A, non-B hepatitis virus polynucleotides
EP0423239A1 (en) Post-transfusion, non-a, non-b hepatitis virus and antigens
US10287335B2 (en) HCBI sequences as an early marker for the future development of cancer and diseases of the CNS and as a target for cancer treatment and prevention
JPH08504096A (ja) Ｅ型肝炎パキスタン株の組換えタンパク質ならびに診断法およびワクチンにおけるそれらの利用
WO2021206638A1 (en) Vaccine and/or antibody for viral infection
JP2007513604A (ja) 新規エンテロウイルス、ワクチン、医薬および診断キット
Ma et al. Sequence addition to the N-or C-terminus of the major capsid protein VP1 of norovirus affects its cleavage and assembly into virus-like particles
US20030198947A1 (en) Hepatitis virus sentinel virus I (SVI)
JP2001524821A (ja) Ｅ型肝炎のパキスタン株組換えタンパク質および診断法およびワクチンにおけるそれらの使用
Gao et al. Receptor profile and immunogenicity of the non-epidemic norovirus GII. 8 variant
US7105165B2 (en) Mutant human hepatitis B viral strain and uses thereof
McClenahan et al. Expression and self-assembly of virus-like particles from two genotypes of marine vesiviruses and development of an ELISA for the detection of antibodies
KR100430935B1 (ko) 대장균 발현 재조합 3ａｂｃ 비구조단백질 및단클론항체를 이용한 구제역 진단방법
CN121494944A (zh) 一种马尔堡gp蛋白突变体、dna分子、重组载体及其应用
CN117098846A (zh) 诺如病毒来源的肽、多核苷酸、抗体、组合物、鉴定诺如病毒的中和表位的方法
CN118647391A (zh) 抗原性多肽及其用途
Loureiro et al. the conserved VP0 protein [version 1; referees: awaiting peer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210721

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20211202

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20211206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220504

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220505

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240116